Clinical effect observation for early tirofiban application in acute myocardial infarction patients with multi-vessel coronary artery disease undergoing percutaneous coronary intervention

杨洋,夏豪,刘浙波,李晶
DOI: https://doi.org/10.3969/j.issn.1009-6469.2016.11.039
2016-01-01
Abstract:Objective To evaluate theefficacy and safety of tirofiban in treatment of patientssuffering from acute myocardial infarction with multivessel diseases undergoing percutaneous coronary intervention.Methods A total of 196 patients of acute myocardial infarction with multi-vessel coronary artery disease who received PCI were randomized into tirofiban group(observation group,n =84) and non-tirofiban group(control group,n =112)according to whether or not tirofiban was used during PCI procedure.The observationgroup usedtirofibanon the basis of preoperative conventional treatment,while thecontrol groupdidnot usetirofiban.Basic clinical data,laboratory results,therapeutic use of drugs,coronary artery disease characteristics and major adverse cardiovascular events during the 6-monthfol-low-up and bleeding complications were observed and compared betweenthe two groups.Results There were no statistically significant differences in basic clinical data,therapeutic use of drugs and coronary artery disease characteristics between the two groups(P >0.05).During the 6-month follow-up,the incidence of MACE in the observation group was significantly lower than that of controlgroup (P <0.05).There were no significant differences in adverse reaction and clinical bleeding complications(P >0.05).Conclusions Early tirofiban application can effectively reduceincidence of MACE on patients suffering from acute coronary syndrome with multivessel diseases undergoing percutaneous coronary intervention,and there is no increase in bleeding complications.Therefore,tirofiban is an ef-fectiveand safe antiplatelet drug in the treatment of AMI.
What problem does this paper attempt to address?